Novo Nordisk A/S $NVO Position Boosted by North Star Asset Management Inc.

North Star Asset Management Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 19.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,464 shares of the company’s stock after purchasing an additional 6,752 shares during the period. North Star Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,862,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Kingstone Capital Partners Texas LLC raised its position in shares of Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after acquiring an additional 10,001,898 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $370,272,000. Amundi lifted its position in shares of Novo Nordisk A/S by 49.1% in the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after buying an additional 1,627,051 shares during the last quarter. Bank of Montreal Can grew its position in shares of Novo Nordisk A/S by 101.4% during the 2nd quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after buying an additional 1,246,467 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after acquiring an additional 1,038,137 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating for the company in a report on Tuesday. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 13th. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $57.40.

Novo Nordisk A/S Trading Down 5.5%

Shares of NVO stock opened at $44.99 on Tuesday. The firm has a market capitalization of $200.88 billion, a PE ratio of 12.36, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $112.52. The stock has a fifty day moving average of $53.71 and a two-hundred day moving average of $60.14.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The business had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.